134 related articles for article (PubMed ID: 25557364)
1. ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma.
Nagymanyoki Z; Mutter GL; Hornick JL; Cibas ES
Cancer Cytopathol; 2015 Apr; 123(4):253-7. PubMed ID: 25557364
[TBL] [Abstract][Full Text] [Related]
2. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG
J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic pitfalls of peritoneal washing cytology and the role of cell blocks in their diagnosis.
Selvaggi SM
Diagn Cytopathol; 2003 Jun; 28(6):335-41. PubMed ID: 12768641
[TBL] [Abstract][Full Text] [Related]
4. Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
Yen TT; Miyamoto T; Asaka S; Chui MH; Wang Y; Lin SF; Stone RL; Fader AN; Asaka R; Kashima H; Shiozawa T; Wang TL; Shih IM; Tanner EJ
Gynecol Oncol; 2018 Sep; 150(3):426-431. PubMed ID: 30126589
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer.
Raffone A; Travaglino A; Saccone G; Cieri M; Mascolo M; Mollo A; Insabato L; Zullo F
APMIS; 2019 Sep; 127(9):597-606. PubMed ID: 31237034
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of mutated ARID1A inhibited endometrial cancer cell proliferation and stimulated cell apoptosis.
Ye Y; Wei B; Xiaowei X
J BUON; 2018; 23(4):1082-1091. PubMed ID: 30358215
[TBL] [Abstract][Full Text] [Related]
7. Reactive oxygen species downregulate ARID1A expression via its promoter methylation during the pathogenesis of endometriosis.
Xie H; Chen P; Huang HW; Liu LP; Zhao F
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4509-4515. PubMed ID: 29131266
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer.
Rahman M; Nakayama K; Rahman MT; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Miyazaki K
Hum Pathol; 2013 Jan; 44(1):103-9. PubMed ID: 22939958
[TBL] [Abstract][Full Text] [Related]
9. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder.
Faraj SF; Chaux A; Gonzalez-Roibon N; Munari E; Ellis C; Driscoll T; Schoenberg MP; Bivalacqua TJ; Shih IeM; Netto GJ
Hum Pathol; 2014 Nov; 45(11):2233-9. PubMed ID: 25175170
[TBL] [Abstract][Full Text] [Related]
10. ARID1A gene mutation in ovarian and endometrial cancers (Review).
Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma.
Zhang ZM; Xiao S; Sun GY; Liu YP; Zhang FH; Yang HF; Li J; Qiu HB; Liu Y; Zhang C; Kang S; Shan BE
Int J Gynecol Cancer; 2014 Mar; 24(3):534-40. PubMed ID: 24557437
[TBL] [Abstract][Full Text] [Related]
12. Cytodiagnosis of endometrial carcinoma and hyperplasia on imprint smears with additional immunocytochemistry using Ki-67 and p53 biomarkers.
Apostolou G; Apostolou N; Nikolaidou C; Kavantzas N; Patsouris E; Athanassiadou P
Cytopathology; 2014 Apr; 25(2):86-94. PubMed ID: 24118263
[TBL] [Abstract][Full Text] [Related]
13. (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.
Borrelli GM; Abrão MS; Taube ET; Darb-Esfahani S; Köhler C; Chiantera V; Mechsner S
Mol Hum Reprod; 2016 May; 22(5):329-37. PubMed ID: 26832958
[TBL] [Abstract][Full Text] [Related]
14. The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression.
Toumpeki C; Liberis A; Tsirkas I; Tsirka T; Kalagasidou S; Inagamova L; Anthoulaki X; Tsatsaris G; Kontomanolis EN
In Vivo; 2019; 33(3):659-667. PubMed ID: 31028182
[TBL] [Abstract][Full Text] [Related]
15. Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies.
Lee SY; Kim DW; Lee HS; Ihn MH; Oh HK; Park DJ; Kim HH; Kang SB
Oncology; 2015; 88(4):234-40. PubMed ID: 25503393
[TBL] [Abstract][Full Text] [Related]
16. Feasibility, Sensitivity, and Specificity of Postprocedure Peritoneal Cytology.
Seagle BL; Dawson M; Samuelson R; Chacho MS; Rutherford TJ; Shahabi S
Reprod Sci; 2015 Jul; 22(7):808-13. PubMed ID: 25488943
[TBL] [Abstract][Full Text] [Related]
17. Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma.
Kim MJ; Gu MJ; Chang HK; Yu E
Histopathology; 2015 Mar; 66(4):508-16. PubMed ID: 25400081
[TBL] [Abstract][Full Text] [Related]
18. ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component.
Nishikimi K; Kiyokawa T; Tate S; Iwamoto M; Shozu M
Histopathology; 2015 Dec; 67(6):866-71. PubMed ID: 25913291
[TBL] [Abstract][Full Text] [Related]
19. Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer.
Aso T; Uozaki H; Morita S; Kumagai A; Watanabe M
Anticancer Res; 2015 Dec; 35(12):6819-27. PubMed ID: 26637902
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal washing cytology.
Shield P
Cytopathology; 2004 Jun; 15(3):131-41. PubMed ID: 15165269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
